| |
CELATOR PRESENTS DATA ON THE ACTIVITY OF CPX-351 AGAINST LEUKEMIA AT THE EUROPEAN HEMATOLOGY ASSOCIATION CONGRESS |
|
| 6/8/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
RELAXIN FOR AHF IS THE STRONGEST PREDICTOR OF IMPROVED LONGER-TERM OUTCOMES FOLLOWING HOSPITAL DISCHARGE WHEN COMPARED TO OTHER VARIABLES |
|
| 6/1/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
RESULTS AND ADDITIONAL ANALYSES FROM EFFICACY AND SAFETY STUDY OF CORTHERA’S RELAXIN IN ACUTE HEART FAILURE TO BE PRESENTED AT HEART FAILURE CONGRESS |
|
| 5/28/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
CLOVIS ONCOLOGY RAISES $145 MILLION IN START-UP FINANCING |
|
| 5/21/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® PHARMACEUTICALS INITIATES RESEARCH AGREEMENT WITH CEPHALON, INC. |
|
| 5/21/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® PHARMACEUTICALS TO PRESENT AT 2009 BIO INTERNATIONAL CONVENTION |
|
| 5/13/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
ALTEA THERAPEUTICS ANNOUNCES SENIOR R&D MANAGEMENT APPOINTMENTS |
|
| 5/5/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
EVOKE PHARMA, INC. INITIATES PHASE 2B METOCLOPRAMIDE INTRANASAL TRIAL (MINT) IN PATIENTS WITH DIABETIC GASTROPARESIS |
|
| 5/5/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® PHARMACEUTICALS PRESENTS NEW DATA ON CPX-351 and CPX-1 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH |
|
| 4/22/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
VENTIRX INITIATES PHASE I TRIAL OF VTX-1463, A NOVEL TLR8 AGONIST FOR THE TREATMENT OF ALLERGIC RHINITIS |
|
| 4/16/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
SANOFI-AVENTIS TO ACQUIRE BIPAR SCIENCES |
|
| 4/15/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
ALTEA THERAPEUTICS ANNOUNCES AGREEMENT WITH AMYLIN AND LILLY FOR AN INVESTIGATIONAL TRANSDERMAL EXENATIDE |
|
| 4/1/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
RESULTS FROM STUDY SHOW PROMISING EFFICACY AND SAFETY RESULTS FOR CORTHERA’S RELAXIN IN ACUTE HEART FAILURE |
|
| 3/29/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
MARINUS PHARMACEUTICALS, INC. ANNOUNCES POSITIVE RESULTS OF ITS PHASE 2 CLINICAL TRIAL OF GANAXOLONE AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSE |
|
| 3/3/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
ASCENTA THERAPEUTICS ANNOUNCES POSITIVE PRELIMINARY RESULTS WITH AT-101 IN DOCETAXEL REFACTORY PROSTATE CANCER |
|
| 2/27/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
NOVALAR ANNOUNCES THE LAUNCH OF ORAVERSE™ THE FIRST DENTAL ANESTHESIA REVERSAL AGENT |
|
| 2/27/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
MERITAGE PHARMA INITIATES PHASE 2B CLINICAL TRIAL OF ORAL VISCOUS BUDESONIDE FOR PEDIATRIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS |
|
| 1/22/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
LEUKEMIA & LYMPHOMA SOCIETY AND CELATOR ANNOUNCE PARTNERSHIP TO ACCELERATE DEVELOPMENT OF CPX-351 FOR AML |
|
| 1/22/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
VENTIRX PHARMACEUTICALS COMMENCES PHASE I CLINICAL TRIAL OF VTX-2337, A NOVEL TLR8 AGONIST FOR THE TREATMENT OF ONCOLOGY |
|
| 12/4/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR PHARMACEUTICALS TO PRESENT AT PIPER JAFFRAY HEALTH CARE CONFERENCE and MID-ATLANTIC CAPITAL CONFERENCE |
|
| 11/25/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR PHARMACEUTICALS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2 STUDY WITH CPX-351 |
|
| 11/18/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
INTERIM ANALYSIS OF TOP-LINE DATA FROM PHASE II/III STUDY SHOWS FAVORABLE EFFICACY & SAFETY FOR CORTHERA’S RELAXIN IN ACUTE HEART FAILURE |
|
| 11/10/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
BIPAR SCIENCES' LEAD COMPOUND SELECTED AS TOP 10 ONCOLOGY DRUG CANDIDATE |
|
| 10/28/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
MARINUS COMPLETES TWO PHASE 2 MILESTONES FOR GANAXOLONE IN EPILEPSY |
|
| 10/7/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ALIMERA REPORTS RESULTS FROM THE SIX-MONTH INTERIM READOUT OF THE HUMAN PK ILUVIEN™ STUDY |
|
| 10/1/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
OCEANA THERAPEUTICS COMMENCES OPERATIONS AFTER COMPLETING SERIES A FINANCING ROUND |
|
| 9/29/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
GI DYNAMICS ANNOUNCES SHORT-TERM WEIGHT LOSS RESULTS IN MORBIDLY OBESE PATIENTS |
|
| 9/26/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
GI DYNAMICS ANNOUNCES DATA THAT SHOWS ENDOBARRIER REDUCES HBA1C IN PATIENTS WITH TYPE 2 DIABETES |
|
| 9/16/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
FIVEPRIME INITIATES PHASE I OF FP-1039 IN PATIENTS WITH ADVANCED CANCERS |
|
| 9/8/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
COLUCID PRESENTS PHASE II RESULTS OF COL-144 AT THE EUROPEAN HEADACHE AND MIGRAINE TRUST INTERNATIONAL CONGRESS 2008 |
|
| 9/5/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
REGADO BIOSCIENCES REPORTS CLINICAL RESULTS FOR REG1 ANTICOAGULATION SYSTEM AT EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2008 |
|
| 9/4/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR RECEIVES ORPHAN DRUG DESIGNATION FOR CPX-351 |
|
| 9/4/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ZOGENIX CLOSES $18 MILLION FINANCING WITH OXFORD FINANCE CORPORATION AND CIT HEALTHCARE LLC |
|
| 8/5/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
MARINUS APPOINTS JOHN KRAYACICH AS PRESIDENT AND CEO |
|
| 8/5/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
DAVID J. MAZZO, PH.D., JOINS REGADO BIOSCIENCES AS PRESIDENT AND CEO |
|
| 8/4/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR RAISES SERIES C FINANCING IN EXCESS OF $22.5 MILLION |
|
| 7/28/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ALTEA PARTNERS TRANSDERMAL PRODUCT WITH HOSPIRA |
|
| 7/2/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
COLUCID CLOSES $25 MILLION SERIES B FINANCING |
|
| 7/1/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ZOGENIX TO PRESENT DOSEPRO RESULTS AT ANNUAL AMERICAN HEADACHE SOCIETY MEETING |
|
| 6/28/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ALIMERA REPORTS RESULTS FROM THE THREE-MONTH INTERIM READOUT OF THE HUMAN PK MEDIDUR FA STUDY |
|
| 6/26/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
VANDA ANNOUNCES POSITIVE TOP-LINE PHASE III DATA OF TASIMELTON IN ADULTS WITH CHRONIC INSOMNIA |
|
| 6/26/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELL BIOSCIENCES ANNOUNCES NEW LEADERSHIP |
|
| 6/24/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
MERITAGE ACQUIRES PEDIATRIC GASTROINTESTINAL PROGRAM FROM VERUS PHARMACEUTICALS |
|
| 6/16/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
MERITAGE PHARMA CLOSES $22.5 MILLION SERIES A FINANCING |
|
| 6/16/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
GIDYNAMICS PRESENTS INITIAL RESULTS AT ADA |
|
| 6/13/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
GENVAULT CORPORATION RAISES $13 MILLION OF VENTURE FINANCING |
|
| 6/9/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN: CONTRAVE MAY REVERSE THE INCIDENCE OF METABOLIC SYNDROME |
|
| 6/7/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
VANDA AND LABCORP COLLABORATE TO OFFER GENETIC TESTS |
|
| 6/5/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR REPORTS POSITIVE PHASE 2 DATA FOR CPX-1 IN COLORECTAL CANCER |
|
| 6/3/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
VENTIRX APPOINTS DR. ELLIOT GROSSBARD TO BOARD OF DIRECTORS |
|
| 5/20/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
FIVEPRIME AND PFIZER ENTER ONCOLOGY AND DIABETES COLLABORATION |
|
| 5/20/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
NOVALAR RECEIVES FDA APPROVAL FOR ORAVERSE |
|
| 5/12/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR PHARMACEUTICALS APPOINTS SCOTT JACKSON AS CEO |
|
| 5/9/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
FIVE PRIME REPORTS DISCOVERY OF IL-34, A NOVEL CYTOKINE |
|
| 5/8/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ESPERION THERAPEUTICS COMPLETES $22.75M SERIES A FINANCING |
|
| 5/1/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
NUON THERAPEUTICS INC. COMPLETES $27M SERIES B FINANCING |
|
| 4/28/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN COMPLETES ENROLLMENT OF SECOND PHASE III CONTRAVE TRIAL |
|
| 4/22/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
TARGETRX COMPLETES $9.6MM FINANCING ROUND |
|
| 4/7/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ORQIS MEDICAL PRESENTS MOMENTUM TRIAL RESULTS AT ACC |
|
| 4/1/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
DIOBEX ANNOUNCES PRESENTATION OF SCIENTIFIC POSTER AT ANNUAL MEETING OF AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS |
|
| 4/1/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
FDA ACCEPTS ZOGENIX NDA FILING |
|
| 3/19/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
DIOBEX AND CAMURUS SIGN LICENSE AGREEMENT FOR THE DEVELOPMENT OF DIO-901 IN FLUIDCRYSTAL EXTENDED RELEASE TECHNOLOGY |
|
| 3/18/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ALIMERA SCIENCES CLOSES $30 MILLION SERIES C FINANCING |
|
| 3/18/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
SCIELE PHARMA ACQUIRES TWINJECT FROM VERUS PHARMACEUTICALS |
|
| 3/13/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
PHARMION SHAREHOLDERS APPROVE ACQUISTION BY CELGENE |
|
| 3/6/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELGENE TO ACQUIRE PHARMION FOR $2.9B |
|
| 11/19/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
CELGENE TO ACQUIRE PHARMION FOR $2.9B |
|
| 11/19/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
CELGENE TO ACQUIRE PHARMION FOR $2.9B |
|
| 11/19/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
CELGENE TO ACQUIRE PHARMION FOR $2.9B |
|
| 11/19/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
CELGENE TO ACQUIRE PHARMION FOR $2.9B |
|
| 11/19/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
NOVALAR RAISES $30M IN SERIES D FINANCING |
|
| 10/26/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN RELEASES SUMMARY OF POSITIVE PHASE 2B CONTRAVE RESULTS IN OBESITY |
|
| 10/21/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
VERUS DIVESTS PEDIATRIC ASTHMA PROGRAM TO ASTRAZENECA |
|
| 10/8/2007 |
|
|
more
|
| |
| |
|
